Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Inks Commercialization Deal for miRNA Tests with Genetic Technologies

Premium

Rosetta Genomics this week announced that it has signed an agreement making Australia's Genetic Technologies the exclusive distributor of its three miRview microRNA-based diagnostics in Australia, New Zealand, and Singapore.

Under the deal, Genetic Technologies will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

"This is an important first step in Genetic Technologies' move from predictive gene tests into advanced cancer management," Genetic Technologies CEO Paul MacLeman said in a statement.

Financial terms of the arrangement were not disclosed.

Rosetta's arrangement with Genetic Technologies comes a little more than a month after the miRNA shop licensed the Italian rights to the diagnostics to AXA Diagnostics (see RNAi News, 9/10/2009).

In August, Rosetta announced that it has licensed the rights to the diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories (see RNAi News, 8/20/2009). That same month, Rosetta licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).

In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). Prometheus has since launched the tests under its ProOnc line (see RNAi News, 10/15/2009).

In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.